Hans Van der Vliet

Company: LAVA Therapeutics

Job title: Chief Scientific Officer

Seminars:

Bispecific Vγ9Vδ2-T Cell Engagers for Immunotherapy of Solid & Hematological Malignancies 9:30 am

Discussing the design and preclinical work to demonstrate efficacy and safety of bispecific engagers directed against Vγ9Vδ2-T cells Highlighting the tri-specific properties of a CD1d-Vδ2 bispecific T cell engager Presentation of early clinical and pharmacodynamics data from phase 1 programsRead more

day: Conference Day Two